Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HHAT | Q5VTY9 | 3/20 | 0.60 |
| ▸ | PRCP | P42785 | 2/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.58 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.58 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.58 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.58 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.58 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12226990 | 1.00 | HHAT (0.60) | HHATPRCPCHRM3CHRM2CHRM1 | |
| SCHEMBL1122195 | 1.00 | HHAT (0.60) | HHATPRCPCHRM3CHRM2CHRM1 | |
| SCHEMBL4250247 | 1.00 | HHAT (0.60) | HHATPRCPCHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4631703 | 0.98 | HHAT (0.58) | HHATPRCPCHRM3CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL8903394 | 0.98 | HHAT (0.58) | HHATPRCPCHRM3CHRM2CHRM1 | |
| Oxalic Acid SCHEMBL2995637 | 0.97 | HHAT (0.57) | HHATPRCPCHRM3CHRM2CHRM1 | |
| Succinic Acid SCHEMBL6822306 | 0.93 | CHRM3 (0.62) | HHATPRCPCHRM3CHRM2CHRM1 | |
| Succinic Acid SCHEMBL2849101 | 0.93 | CHRM3 (0.62) | HHATPRCPCHRM3CHRM2CHRM1 | |
| SCHEMBL4632573 | 0.92 | HHAT (0.59) | HHATPRCPCHRM3CHRM2CHRM1 | |
| Cadaverine Tartrate SCHEMBL5985676 | 0.92 | CYP2D6 (0.58) | HHATPRCPCHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190152917-A1 | ABHD6 AND DUAL ABHD6/MGL INHIBITORS AND THEIR USES | MAKSCIENTIFIC, LLC | 2019-05-23 | — | — | US | claimed |
| US-20170231974-A1 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent | ASTELLAS IRELAND CO., LTD. (IE) | 2017-08-17 | — | — | US | claimed |
| US-9399624-B2 | Process for preparing (1S)-1-phenyl-3,4-dihydro-2(1H)-isoquinoline-carboxylate | SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (CN) | 2016-07-26 | — | — | US | claimed |
| US-20150225348-A1 | PROCESS FOR PREPARING (1S)-1-PHENYL-3,4-DIHYDRO-2(1H)-ISOQUINOLINE-CARBOXYLATE | Shangyu Jingxin Pharmaceutical Co., Ltd. (CN) | 2015-08-13 | — | — | US | claimed |
| US-8772315-B2 | Pharmaceutical composition for treating overactive bladder | ASTELLAS PHARMA INC. (JP) | 2014-07-08 | — | — | US | claimed |
| US-8772491-B2 | Process for the preparation of solifenacin succinate | AUROBINDO PHARMA LTD (IN) | 2014-07-08 | — | — | US | claimed |
| US-20130267557-A1 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent | ASTELLAS IRELAND CO., LTD. (IE) | 2013-10-10 | — | — | US | claimed |
| US-20130150402-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | ASTELLAS PHARMA INC. (JP) | 2013-06-13 | — | — | US | claimed |
| US-20130123502-A1 | NOVEL PROCESS FOR THE PREPARATION OF SOLIFENACIN SUCCINATE | AUROBINDO PHARM LTD. (IN) | 2013-05-16 | — | — | US | claimed |
| EP-2216021-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | ASTELLAS PHARMA INC (JP) | 2012-10-17 | — | — | EP | claimed |
| EP-1880718-B1 | Pharmaceutical preparation for oral administration with controlled drug release in the small intestine colon and process of prepartion thereof | PFLEGER R CHEM FAB (DE) | 2011-09-21 | — | — | EP | claimed |
| US-20100331361-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ALPHA-ADRENERGIC RECEPTOR ANTAGONIST AND AN ANTI-MUSCARINIC AGENT AND METHOD OF IMPROVING LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH PROSTATIC HYPERTROPHY | ASTELLAS PHARMA INC. (JP) | 2010-12-30 | — | — | US | claimed |
| US-20100298371-A1 | PROCESS FOR PREPARING CHEMICALLY AND CHIRALLY PURE SOLIFENACIN BASE AND ITS SALTS | CADILA HEALTHCARE LIMITED (IN) | 2010-11-25 | — | — | US | claimed |
| US-20100240697-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | ASTELLAS PHARMA INC. (JP) | 2010-09-23 | — | — | US | claimed |
| EP-2229387-A1 | PROCESS FOR PREPARING CHEMICALLY AND CHIRALLY PURE SOLIFENACIN BASE AND ITS SALTS | Cadila Healthcare Limited (IN) | 2010-09-22 | — | — | EP | claimed |
| EP-2216021-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | claimed |
| CN-101754760-A | Pharmaceutical composition for amelioration of lower urinary tract symptom associated with prostatomegaly | ASTELLAS PHARMA INC | 2010-06-23 | — | — | CN | claimed |
| EP-2181707-A1 | Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent | Astellas Ireland Co., Ltd. (IE) | 2010-05-05 | — | — | EP | claimed |
| EP-2172201-A1 | PHARMACEUTICAL COMPOSITION FOR AMELIORATION OF LOWER URINARY TRACT SYMPTOM ASSOCIATED WITH PROSTATOMEGALY | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | claimed |
| WO-2009087664-A1 | PROCESS FOR PREPARING CHEMICALLY AND CHIRALLY PURE SOLIFENACIN BASE AND ITS SALTS | CADILA HEALTHCARE LIMITED (IN) | 2009-07-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267557-A1 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent | ADRB1, ADRB2, ADRB3 | HHAT 2600/4885PRCP 1388/4885CHRM3 11/4885 |
| US-20130123502-A1 | NOVEL PROCESS FOR THE PREPARATION OF SOLIFENACIN SUCCINATE | SUCNR1, SUCLG2, SUCLA2 | HHAT 2645/4885PRCP 2004/4885CHRM3 33/4885 |
| US-20170231974-A1 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent | ADRB1, ADRB2, ADRB3 | HHAT 2600/4885PRCP 1388/4885CHRM3 11/4885 |
| US-20190152917-A1 | ABHD6 AND DUAL ABHD6/MGL INHIBITORS AND THEIR USES | ABHD6, FAAH, FAAH2 | HHAT 268/4885PRCP 2595/4885CHRM3 1716/4885 |
| US-20130150402-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | BPHL, PDE12, UROD | HHAT 2564/4885PRCP 1401/4885CHRM3 68/4885 |
| US-20150225348-A1 | PROCESS FOR PREPARING (1S)-1-PHENYL-3,4-DIHYDRO-2(1H)-ISOQUINOLINE-CARBOXYLATE | IDH3A, POLG, IDH3B | HHAT 4453/4885PRCP 2271/4885CHRM3 1644/4885 |
| US-20100240697-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | BPHL, PDE12, UROD | HHAT 2434/4885PRCP 1074/4885CHRM3 35/4885 |
| US-20100331361-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ALPHA-ADRENERGIC RECEPTOR ANTAGONIST AND AN ANTI-MUSCARINIC AGENT AND METHOD OF IMPROVING LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH PROSTATIC HYPERTROPHY | ADRB1, ADRA2B, ADRB3 | HHAT 4105/4885PRCP 1393/4885CHRM3 11/4885 |
| US-20100298371-A1 | PROCESS FOR PREPARING CHEMICALLY AND CHIRALLY PURE SOLIFENACIN BASE AND ITS SALTS | OPRL1, CHRNB1, OPRK1 | HHAT 3237/4885PRCP 726/4885CHRM3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.